Related Experiment Video
Updated: May 24, 2026
09:29
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Variable results after rituximab in neuromyelitis optica
J W Lindsey1, K M Meulmester, S A Brod
1Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA. John.w.lindsey@uth.tmc.edu
Journal of the Neurological Sciences
|March 13, 2012
Summary
Rituximab (RTX) shows inconsistent efficacy for neuromyelitis optica (NMO) and related conditions. Many patients continued to experience relapses even after RTX treatment, indicating a need for more effective therapies.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Autoimmune Diseases
Background:
- Neuromyelitis optica (NMO) is a severe autoimmune disorder affecting the central nervous system.
- Rituximab (RTX), a B-cell depleting agent, has been used off-label for NMO management.
- Assessing RTX efficacy in NMO is crucial for guiding treatment strategies.
Observation:
- A retrospective review of nine patients with NMO or LETM treated with RTX was conducted.
- Six out of nine patients experienced relapses post-RTX treatment.
- In five patients, RTX was the initial immunosuppressive therapy, yet four still relapsed.
Findings:
- Rituximab treatment outcomes for NMO are variable and not consistently effective.
- A significant proportion of patients treated with RTX continue to have disease relapses.
- The effectiveness of RTX may be influenced by individual disease activity or immunopathogenesis.
Implications:
- Current RTX treatment protocols for NMO may require re-evaluation.
- Further research into the immunopathogenesis of NMO is needed to develop targeted therapies.
- There is a clear need for more effective and consistent treatments for NMO patients.
